Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride
- PMID: 22015966
- DOI: 10.1007/s13318-011-0070-9
Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride
Abstract
The field of ocular drug delivery is one of the interesting and challenging endeavors facing the pharmaceutical scientist. Novel approaches for ophthalmic drug delivery need to be established to increase the ocular bioavailability by overcoming the inherent drawbacks of conventional dosage forms. In situ hydrogels are instilled as drops into the eye and undergoes a sol-to-gel transition in the cul-de-sac, improved ocular bioavailability by increasing the duration of contact with corneal tissue, thereby reducing the frequency of administration. The purpose of the present work was to develop an ophthalmic drug delivery system using three different gelling agents with different mechanisms for in situ gelation of Moxifloxacin hydrochloride, a fluoroquinolone antibiotic. polyox (a pH-sensitive gelling agent), sodium alginate (an ion-sensitive gelling agent), and poloxamer (a temperature-sensitive gelling agent) were employed for the formation of in situ hydrogel along with HPMC K4M as viscofying agent, which increases the residence time of the drug in the ocular cavity. The promising formulations MF(4), MF(5), and MF(9) were evaluated for pH, drug content, in vitro gelation, in vitro drug release, in vivo drug release, ocular irritation, and stability. Percent drug content of 98.2, 98.76, and 99.43%; viscosity of 15.724 × 100, 16.108 × 100, and 15.213 × 100 cP at 20 rpm, cumulative percent release of 75.364, 74.081, and 71.752%, and C (max) of 1,164.16, 1,187.09, and 1,220.58 ng/ml was observed for formulation MF(4), MF(5), and MF(9), respectively. The developed formulations were therapeutically efficacious, stable, and non-irritant and provided sustained release of the drug over 8 h.
Similar articles
-
Design and Development of Thermoreversible Ophthalmic In Situ Hydrogel of Moxifloxacin HCl.Curr Drug Deliv. 2010 Jul;7(3):238-43. doi: 10.2174/156720110791560928. Curr Drug Deliv. 2010. PMID: 20497100
-
Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery: in vitro and ex vivo characterization.Pharm Dev Technol. 2015;20(6):662-9. doi: 10.3109/10837450.2014.910807. Epub 2014 Apr 23. Pharm Dev Technol. 2015. PMID: 24754411
-
Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.Int J Pharm. 2006 Jun 6;315(1-2):12-7. doi: 10.1016/j.ijpharm.2006.01.029. Epub 2006 Apr 17. Int J Pharm. 2006. PMID: 16616442
-
Recent advances in ocular drug delivery.Drug Dev Ind Pharm. 2013 Nov;39(11):1599-617. doi: 10.3109/03639045.2012.736515. Epub 2012 Nov 16. Drug Dev Ind Pharm. 2013. PMID: 23153114 Review.
-
Safety of moxifloxacin as shown in animal and in vitro studies.Surv Ophthalmol. 2005 Nov;50 Suppl 1:S46-54. doi: 10.1016/j.survophthal.2005.05.003. Surv Ophthalmol. 2005. PMID: 16257310 Review.
Cited by
-
Development of a Temperature and pH Dual-Sensitive In-Situ Gel for Treating Allergic Conjunctivitis.AAPS PharmSciTech. 2024 Sep 25;25(7):223. doi: 10.1208/s12249-024-02931-6. AAPS PharmSciTech. 2024. PMID: 39322789
-
Ophthalmic In Situ Gels with Balsam Poplar Buds Extract: Formulation, Rheological Characterization, and Quality Evaluation.Pharmaceutics. 2021 Jun 24;13(7):953. doi: 10.3390/pharmaceutics13070953. Pharmaceutics. 2021. PMID: 34202901 Free PMC article.
-
Microneedle-mediated intrascleral delivery of in situ forming thermoresponsive implants for sustained ocular drug delivery.J Pharm Pharmacol. 2014 Apr;66(4):584-95. doi: 10.1111/jphp.12152. Epub 2013 Oct 16. J Pharm Pharmacol. 2014. PMID: 24127904 Free PMC article.
-
Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.Pharmaceutics. 2018 Jan 13;10(1):10. doi: 10.3390/pharmaceutics10010010. Pharmaceutics. 2018. PMID: 29342879 Free PMC article. Review.
-
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications.Ann Med. 2022 Dec;54(1):343-358. doi: 10.1080/07853890.2021.1955146. Ann Med. 2022. PMID: 35076329 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous